Peritoneal Metastases: Evolution from a Dark Horizon to an Encouraging Present and a Promising Future

Affiliations

¹ General Surgery Service, University Hospital Príncipe de Asturias, 28820 Alcalá de Henares, Spain.
² Medical Oncology Service, University Hospital Príncipe de Asturias, 28820 Alcalá de Henares, Spain.
³ Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá de Henares, 28880 Alcala de Henares, Spain.

Editorial

Manuel Diez-Alonso et al. J Clin Med. 2023.

. 2023 Dec 6;12(24):7536.

doi: 10.3390/jcm12247536.

¹ General Surgery Service, University Hospital Príncipe de Asturias, 28820 Alcalá de Henares, Spain.
² Medical Oncology Service, University Hospital Príncipe de Asturias, 28820 Alcalá de Henares, Spain.
³ Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá de Henares, 28880 Alcala de Henares, Spain.

Abstract

Peritoneal metastasis (PM) is the primary pattern of metastasis for primary tumours of the appendix, ovary, and peritoneal mesothelioma [...].

The authors declare no conflict of interest.

1. Lambert L.A. Looking Up: Recent Advances in Understanding and treating Peritoneal Carcinomatosis. CA Cancer J. Clin. 2015;65:283–298. doi: 10.3322/caac.21277. - DOI - PubMed
1. Baaten I.C.P.A., West N.P., Quyn A.J., Seymour M.T., Seligmann J.F. Colorectal cancer peritoneal metastases: Biology, treatment and next steps. Eur. J. Surg. Oncol. 2020;46:675–683. doi: 10.1016/j.ejso.2019.10.035. - DOI - PubMed
1. Sánchez-Hidalgo J.M., Rodríguez-Ortiz L., Arjona-Sánchez Á., Rufián-Peña S., Casado-Adam Á., Cosano-Álvarez A., Briceño-Delgado J. Colorectal peritoneal metastases: Optimal management review. World J. Gastroenterol. 2019;25:3484–3502. doi: 10.3748/wjg.v25.i27.3484. - DOI - PMC - PubMed
1. Van Cutsem E., Cervantes A., Adam R., Sobrero A., Van Krieken J.H., Aderka D., Aguilar E.A., Bardelli A., Benson A., Bodoky G., et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann. Oncol. 2016;27:1386–1422. doi: 10.1093/annonc/mdw235. - DOI - PubMed
1. Sanoff H.K., Sargent D.J., Campbell M.E., Morton R.F., Fuchs C.S., Ramanathan R.K., Williamson S.K., Findlay B.P., Pitot H.C., Goldberg R.M. Five-year data and prognostic factor Analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J. Clin. Oncol. 2008;26:5721–5727. doi: 10.1200/JCO.2008.17.7147. - DOI - PMC - PubMed